杜皮鲁玛
特应性皮炎
医学
队列
人口
疾病
队列研究
皮肤病科
儿科
内科学
环境卫生
作者
Serena Yun‐Chen Tsai,Jonathan M. Gaffin,Elena B. Hawryluk,Hana B. Ruran,Lisa M. Bartnikas,Michiko K. Oyoshi,Lynda C. Schneider,Marissa Hauptman,Kevin Sheng‐Kai
出处
期刊:Allergy
[Wiley]
日期:2024-08-21
摘要
Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI